SEC Form 4 · accession 0001209191-17-065442
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Anthony Cannon
Director
Period of report
Dec 12, 2017
Accepted (ET)
Dec 13, 2017 · 4:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 12, 2017 | M | 20,000 | $2.73 | A | 387,502 | D | |
| Common StockF1 | Dec 12, 2017 | F | 13,094 | $4.17 | D | 374,408 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.73 | Dec 12, 2017 | M | 20,000 | D | — | Dec 12, 2017 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1Represents shares withheld to pay exercise price.
- F26,667 shares vested on each of 12/12/08 and 12/12/09; 6,666 shares vested on 12/12/10.